Download Files:
Osimertinib
Price range: 48 CAD through 584 CAD
Products Details
Product Description
– Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.
Web ID
– T2490
Storage Temperature
– -20℃
Shipping
– Blue Ice
Molecular Formula
– C28H33N7O2
Citations
– 1. Liu Y, Lai M, Li S, et al. LS‐106, a novel EGFR inhibitor targeting C797S, exhibits anti‐tumor activities both in vitro and in vivo. Cancer Science. 2021
2. Lv S, Pan Q, Lu W, et al.Tenovin 3 induces apoptosis and ferroptosis in EGFR 19del non small cell lung cancer cells.Scientific Reports.2024, 14(1): 7654.
3. Yu J, Zhang L, Peng J, et al. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochemical pharmacology. 2022, 195: 114864.
4. Shang J, Ning S, Chen Y, et al. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer. Acta Pharmacologica Sinica. 2021, 42(1): 120-131
5. Jin Y, Zhang Y, Huang A, et al.Overexpression of SERPINA3 suppresses tumor progression by modulating SPOP/NF‑κB in lung cancer.International Journal of Oncology.2023, 63(2): 1-16.
6. Liang J, Bi G, Sui Q, et al.Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma.Cell Reports.2024, 43(2).
7. Tan J, Zhu L, Shi J, et al.Evaluation of drug resistance for EGFR-TKIs in Lung Cancer via Multicellular lung-on-a-chip.European Journal of Pharmaceutical Sciences.2024: 106805.
8. Zhang Y, Chen Y, Wang B, et al.A novel selenium nanocomposite modified by AANL inhibits tumor growth by upregulating CLK2 in lung cancer.Bioorganic Chemistry.2024: 107459.
9. Wei X, Zhang G, Liu Q, et al.Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.Clinical and Translational Oncology.2024: 1-16.
10. Zhang C, Sun Y X, Yi D C, et al.Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).Cell Reports Medicine.2024
References
– Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018 Apr;17(4):740-750.
CAS Number
– 1421373-65-0
Molecular Weight
– C28H33N7O2
Compound Purity
– 0.9983
SMILES
– CN1C=C(C=2C1=CC=CC2)C3=NC(NC4=C(OC)C=C(N(CCN(C)C)C)C(NC(C=C)=O)=C4)=NC=C3
Pathway
– Angiogenesis|||JAK/STAT signaling|||Tyrosine Kinase/Adaptors
Product type
– Small Compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
Related Products
1000 in stock
1000 in stock
